Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
THC Farmaceuticals, Inc. (CBDG)
Scottsdale, AZ, US
THC Farmaceuticals, Inc. specializes in the ownership and operation of independent (non-bank) automated teller machines (ATMs), strategically placing them within third-party retail and commercial establishments. These cash-dispensing units are typically situated in bustling commercial spaces such as hotels, stores, and bowling alleys, aiming for high customer footfall areas that often serve small and medium-sized enterprises. By mid-2015 (June 30), the company reported a network of eight public-access ATMs concentrated in Utah's Wasatch Front region. Founded in 2008 and based in Scottsdale, Arizona, the company adopted its current name, THC Farmaceuticals, Inc., in February 2015, having previously operated as City Media, Inc. THC Farmaceuticals, Inc. functions as a subsidiary of Weed Growth Fund, Inc.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | -59.09% | -30.77% | -52.63% | +76.47% | +4,400.00% | -92.74% | -97.27% | -94.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%— Q2'22: -100.0% (vs Q2'19)
-
EPS growth Biotechnology: +29.7%+175.0% ★ Q2'22: +99.3% (vs Q2'19)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-0.8% ★ Q2'22: -1.0% (vs Q2'19)
-
Share dilution Biotechnology: -3.4%+0.0% ★ Q2'22: +9.0% (vs Q2'19)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-7.28× Q2'22: -17.97× (vs Q2'19)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | WEED GROWTH FUND, INC. | 10.51M | 87.80% | 10.51M | — | 10.51M | 10.00 | CO | NEVADA | 2014-11-25 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Ed Rosenthal | President | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CBDG
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
